The earnings call highlighted strong revenue growth and pipeline advancements, alongside effective cost management and strategic collaborations. However, challenges such as a decline in software gross margins, continued net losses, and a difficult biotech sector landscape were also noted. Despite these issues, the positive achievements and future potential suggest a cautiously optimistic outlook.

Company Guidance -

Q3 2025

During Schrodinger's second quarter 2025 financial results conference call, the company provided guidance indicating strong performance despite macroeconomic challenges. Total revenue for the quarter was reported at $54.8 million, marking a 16% increase compared to the same period in 2024. Software revenue grew by 15% year-over-year to $40.5 million, and drug discovery revenue rose by 19% to $14.2 million. The company maintained its full-year software revenue growth guidance of 10% to 15% and drug discovery revenue guidance of $45 million to $50 million. Operating expenses were reported at $79 million, a 6% reduction from the previous year, attributed to a $30 million expense reduction initiative. Schrodinger ended the quarter with $462 million in cash and equivalents. The company also highlighted progress in its therapeutic pipeline, with plans to report initial Phase I data from SGR-2921 and SGR-3515 in the fourth quarter.

Revenue Growth

Total revenue was $54.8 million in the second quarter of 2025, marking a 16% increase from the second quarter of 2024. Software revenue rose by 15% year-over-year to $40.5 million, while drug discovery revenue increased by 19% to $14.2 million.

Pipeline Advancements

The company presented encouraging Phase I data for SGR-1505 and is exploring strategic opportunities to accelerate its clinical development. Additionally, initial Phase I data for SGR-2921 and SGR-3515 are expected in the fourth quarter of 2025.

Cost Management and Financial Health

Operating expenses were reduced by 6% compared to Q2 2024, primarily due to a $30 million expense reduction initiative. The company remains well-capitalized with $462 million in cash and equivalents.

Collaborations and Strategic Partnerships

Schrodinger expanded collaborations with Lilly, Otsuka, and Ajax Therapeutics, and established a new collaboration with the Novo Nordisk Foundation Center for Basic Metabolic Research.

Schrodinger (SDGR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SDGR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.77 / -	-0.52	―	―	―
Aug 06, 2025	2025 (Q2)	-0.77 / -0.59	-0.74	20.27% (+0.15)
May 07, 2025	2025 (Q1)	-0.73 / -0.82	-0.76	-7.89% (-0.06)
Feb 26, 2025	2024 (Q4)	-0.42 / -0.55	-0.32	-71.88% (-0.23)
Nov 12, 2024	2024 (Q3)	-0.63 / -0.52	-0.86	39.53% (+0.34)
Jul 31, 2024	2024 (Q2)	-0.83 / -0.74	0.06	-1333.33% (-0.80)
May 01, 2024	2024 (Q1)	-0.74 / -0.76	1.75	-143.43% (-2.51)
Feb 28, 2024	2023 (Q4)	-0.40 / -0.32	-0.39	17.95% (+0.07)
Nov 01, 2023	2023 (Q3)	-0.69 / -0.86	-0.56	-53.57% (-0.30)
Aug 02, 2023	2023 (Q2)	-0.51 / 0.06	-0.67	108.96% (+0.73)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SDGR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$19.34	$19.36	+0.10%
May 07, 2025	$23.72	$23.88	+0.67%
Feb 26, 2025	$21.70	$22.25	+2.53%
Nov 12, 2024	$19.54	$22.25	+13.87%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.